Medicure: Clinical Trials

9 trials sponsored by Medicure, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 4 Phase 2, 4 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 3, Terminated 1
Phase 34Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1
Phase 11Completed 1

Follow Medicure: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Continuation Study With Oral MC-1 for Treatment of Patients With PNPO-Deficiency
Pyridoxal 5'-Phosphate - Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Phase 3RecruitingMedicure102025-07-152026-11-10
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
Pyridoxal Phosphate - Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Phase 3Active not recruitingMedicure152024-02-162026-11-19
Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function
Tirofiban - Renal Insufficiency
Phase 1CompletedMedicure252013-01-012014-03-27
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Short Tirofiban, Eptifibatide, Long Tirofiban - Myocardial Infarction, Acute Coronary Syndromes
Phase 2CompletedMedicure5352012-04-012021-05-13
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
Pyridoxal 5'-Phosphate, Placebo - Tardive Dyskinesia
Phase 2TerminatedMedicure532009-05-012019-02-15
A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG
(MC-1) Pyridoxal 5'-phosphate - Coronary Artery Bypass Graft Surgery, Myocardial Ischemia
Phase 3CompletedMedicure30002006-11-012007-11-16
MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)
pyridoxal-5'-phosphate with and without ACE inhibitor - Diabetes Mellitus Type 2, Hypertension
Phase 2CompletedMedicure1602004-08-012006-10-31
MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)
(MC-1) Pyridoxal-5'-phosphate - Coronary Artery Bypass Graft Surgery, Myocardial Ischemia
Phase 2CompletedMedicure9002004-04-012006-10-31
Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention
Tirofiban (Aggrastat), Placebo - Myocardial Infarction, Acute Coronary Syndromes
Phase 3WithdrawnMedicure2018-03-13

Conditions studied

Acute Coronary Syndrome (2)  ·  Angina, Unstable (2)  ·  Ischemia (2)  ·  Myocardial Infarction (2)  ·  Myocardial Ischemia (2)  ·  Neurologic Manifestations (2)  ·  Reperfusion Injury (2)  ·  Diabetes Mellitus, Type 2 (1)  ·  Hypertension (1)  ·  Metabolic Syndrome (1)  ·  Renal Insufficiency (1)  ·  Schizophrenia (1)  ·  Tardive Dyskinesia (1)

Interventions

Pyridoxal Phosphate (6)  ·  Tirofiban (3)  ·  Angiotensin-Converting Enzyme Inhibitors (1)  ·  Eptifibatide (1)

Countries

United States (6)  ·  Canada (4)  ·  Australia (2)  ·  India (1)  ·  Poland (1)

Top investigators

Steven V Manoukian, MD (2)  ·  Gary J. Remington, MD, PhD (1)  ·  Jean-Claude Tardif, MD, FRCPC, FACC (1)  ·  John Hill, MD (1)  ·  Michel Carrier, MD (1)  ·  Robert A Harrington, MD (1)  ·  Yves Lacourciere, MD, FRCP (1)

Results publications

PMID 18371465, PMID 18381567